Abstract
BackgroundEpilepsy is a chronic neurological disease. A suitable biomarker for epilepsy diagnosis remains lacking. MicroRNAs (miRNAs) were pronounced as promising biomarkers for epileptogenesis.ObjectivesTo analyze the expression levels of miR 194-5p, miR 106b, and miR 146a in Egyptian epileptic patients compared to control subjects and to detect their correlation to clinical characteristics.Subjects and methodsWe evaluated the expression levels of miR 106b, miR 146a, and miR 194-5p using real-time quantitative polymerase chain reaction (qRT-PCR) in 50 subjects: 15 patients with idiopathic generalized epilepsy, 15 patients with focal epilepsy (3 idiopathic and 12 cryptogenic), and 20 healthy controls.ResultsmiR 106b and miR 194-5p were upregulated in the generalized epilepsy group compared to control; miR 194-5p was significantly downregulated in the focal epilepsy group compared to the generalized epilepsy group and control (p ˂ 0.05). miR 194-5p was negatively correlated to disease duration in patients with focal epilepsy; the three microRNAs were positively correlated to each other (p ˂ 0.05).ConclusionSerum miR 194-5P and miR 106b can be used as potential non-invasive biomarkers in the evaluation of idiopathic generalized epilepsy.
Highlights
Epilepsy is the fourth common neurological disease represented by repeated unprovoked seizures, secondary to episodes of temporary brain dysfunction secondary to abnormal electrical activity
Results: miR 106b and miR 194-5p were upregulated in the generalized epilepsy group compared to control; miR 194-5p was significantly downregulated in the focal epilepsy group compared to the generalized epilepsy group and control (p 0.05). miR 194-5p was negatively correlated to disease duration in patients with focal epilepsy; the three microRNAs were positively correlated to each other (p 0.05)
Serum miR 194-5P and miR 106b can be used as potential non-invasive biomarkers in the evaluation of idiopathic generalized epilepsy
Summary
Epilepsy is the fourth common neurological disease represented by repeated unprovoked seizures, secondary to episodes of temporary brain dysfunction secondary to abnormal electrical activity. Epilepsy represents a high social burden all over the world, with a prevalence of 10.3 per 1000 in developing countries [1]. Biomarkers are needed for accurate diagnosis and treatment, to detect the process. Diagnosis of epilepsy depends on a detailed medical history, clinical examination, electroencephalogram, and neuroimaging. These methods are not sufficient and expensive [4]. Noninvasive, rapid, and more economical biomarkers are still in need of a more accurate diagnosis of epilepsy [5]. A suitable biomarker for epilepsy diagnosis remains lacking.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
